---

$39.28

+0.5450 ( +1.04% ) 175.1K

Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.

Analyst Insights

---

You need to login to view this content.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-08-22	Buy	201546.00	BVF PARTNERS L P/IL
2024-08-22	Buy	1.00	BAKER BROS. ADVISORS LP
2024-07-16	Sale	-16455.00	Gollob Jared
2024-07-09	Sale	-24449.00	Booth Bruce
2024-07-01	Sale	-18773.00	Mainolfi Nello

Reset

Symbol	Issuer Name	Market Value ↓	Share Quantity
No records found.